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rozygous	females	are	also	affected.	We	 identified	and	characterized	a	novel	 IGSF1 
mutation	and	investigated	its	associated	phenotypes	in	a	large	Irish	kindred.




























in TBL1X or IGSF1	may	present	as	isolated	TSH	deficiency.2,4-6
Since	the	initial	description	of	IGSF1	mutations	in	eleven	European	
kindreds,	larger	studies	have	substantiated	the	complex	nature	of	the	




terminal	 immunoglobulin	 loops	 are	 expressed	 extracellularly	 at	 the	













Hormone	 deficiencies	 associated	 with	 IGSF1	 mutations	 may	
involve	all	 cells	of	 the	POU1F1	 lineage.	Hemizygous	males	 almost	
universally	exhibit	central	hypothyroidism	and	60%	have	basal	hy-
poprolactinaemia;	 a	 minority	 (~15%)	 exhibit	 transient	 childhood	
growth	hormone	(GH)	deficiency.9	Endocrine	evaluation	of	hetero-
zygous	females	usually	reveals	a	milder	phenotype	with	FT4	concen-








in	 IGSF1	 deficiency	 (including	 in	 congenic	mouse	 strains),	 and	
some	 individuals	 tolerate	 lifelong	 thyroid	 hormone	 deficiency	
without	apparent	adverse	consequences,	whereas	others	pres-
ent	symptomatically	early	on.4,9,11	Here,	we	describe	a	large	Irish	
kindred	 in	 which	 two	male	 siblings	 with	 CeCH	were	 found	 to	
harbour	a	novel	missense	IGSF1	mutation.	In	vitro	evaluation	of	
the	mutant	 IGSF1	protein	demonstrated	reduced	plasma	mem-
brane	 expression.	 Family	 screening	 identified	 eight	 additional	




bone	 age	 or	 neurodevelopmental	 milestones,	 and	 prolonged	
neonatal	 jaundice.	 Affected	 children	 and	 adults	 may	 also	 ex-
hibit	 bradycardia,	 hypothermia,	 overweight	 and	 dyslipidaemia	
and	may	describe	constipation	and	fatigue.14	Biochemical	sever-
ity	of	hypothyroidism	was	usually	moderate	 in	our	kindred	and	
some	 cases	 appeared	 to	 tolerate	 hypothyroidism	 remarkably	
well,	whereas	seven	individuals	exhibited	adverse	sequelae	po-
tentially	attributable	to	thyroid	hormone	deficiency.	Our	obser-
vations	 support	 the	 notion	 that	 although	 some	 individuals	 are	
apparently	 asymptomatic	 despite	 significant	 central	 hypothy-







Conclusions:	As	observed	with	other	 IGSF1	mutations,	p.L773P	 results	 in	variably	
penetrant	 IGSF1	 deficiency	 syndrome.	 Our	 observations	 emphasize	 the	 need	 for	
multi-	generation	genetic	ascertainment	 in	affected	families,	especially	where	TSH-	
based	CH	screening	programmes	may	fail	to	detect	CeCH	at	birth.
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2.1 | Sanger sequencing of IGSF1
Genomic	DNA	was	extracted	from	peripheral	blood	leukocytes	
using	standard	techniques.	In	the	probands,	all	20	IGSF1	exons	
and	 exon/intron	 boundaries	 were	 amplified	 by	 PCR	 using	
specific	 primers	 (available	 on	 request).	 Family	members	were	
genotyped	 for	 the	 identified	missense	mutation	 (see	 Results)	
by	 amplifying	 and	 sequencing	 exon	 13	 alone.	 PCR	 products	
were	 sequenced	 using	 the	 BigDye	 Terminator	 v3.1	 Cycle	
Sequencing	Kit	(Applied	Biosystems,	Foster	City,	CA)	and	3730	
DNA	Analyzer	 (Applied	 Biosystems).	 The	 IGSF1	 variant	 listed	
in	 this	 study	 is	 described	 using	 the	 systematic	 nomenclature	
approved	 by	 the	 Human	 Genome	 Variation	 Society	 (HGVS;	
www.hgvs.org/mutnomen).	Nucleotide	numbering	starts	from	
the	A	(+1)	of	the	translation	initiation	codon	(ATG)	of	the	NCBI	
reference	 sequence	 NM_001170961.1.	 Amino	 acid	 residues	
are	 numbered	 according	 to	 the	 NCBI	 reference	 sequence	
NP_001164432.
2.2 | Clinical measurements
All	 biochemical	 measurements	 were	 performed	 in	 CPA	 (Clinical	
Pathology	 Accreditation)	 and	 INAB	 (Irish	 National	 Accreditation	
Board)	 accredited	 laboratories,	 using	 local	 automated	 assays,	 and	
results	were	compared	 to	 local	 reference	 ranges	 (age	and	gender-	
specific	 where	 appropriate).	 Auxological	 measurements	 were	
performed	 by	 trained	 auxologists	 during	 clinical	 visits,	 and	 SDS	
scores	 were	 computed	 according	 to	 published	 reference	 data15-17 
using	 GrowthXP	 Endo,	 a	 children	 growth	 monitoring	 commercial	
programme.
Relevant	medical	history	was	acquired	by	review	of	patients’	
notes	 or	 direct	 questioning.	 Unless	 otherwise	 stated,	 refer-
ence	 ranges	 refer	 to	95%	confidence	 intervals,	 and	variance	 is	
reported	 as	 standard	 deviation	 score.	 Sleeping	 heart	 rate	was	
compared	 to	 a	 locally-	generated	 reference	 range	 for	 healthy	
males	and	depicts	minimum	and	maximum.	Basal	metabolic	rate	
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180	minutes	following	administration	of	200	micrograms	of	Protirelin	
(Thyrotrophin-	releasing	 hormone,	 TRH,	 Alliance	 Pharmaceuticals	
Ltd,	 Chippenham,	 UK).	 Hormone	 responses	 were	 compared	 with	





Calculation	 of	 ultrasonographic	 testicular	 volume	 was	 com-
puted	 as	 previously	 described	 and	 compared	 with	 published	
reference	 data.19	 Testicular	 volumes	 in	 children	 were	 assessed	
clinically	by	a	trained	paediatric	endocrinologist	using	the	Prader	
Orchidometer.
2.5 | In vitro analysis of the mutant IGSF1 protein
The	 L773P	 mutation	 was	 introduced	 into	 the	 human	 
myc-	IGSF1-	HA	 expression	 vector	 described	 in8	 using	 the	








The	male	 Proband,	 3a	 (Figure	2),	 was	 born	 at	 term	 to	 nonconsan-
guineous	Irish	parents	(birth	weight	4.7	kg,	SDS	+2.49)	(Figures	2-5;	
Tables	1	and	2;	Tables	S1-	S3).	He	exhibited	mild	 transient	neonatal	











velocity	 declined	 to	 1.91	cm/y	 (height	 velocity	 SDS	 decrease	 from	
+0.1	to	−4.56)	and	growth	declined	from	height	SDS	+0.59	to	+0.21	
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improved	steadily	with	levothyroxine	replacement	(SDS	−4.56	aged	
7.4	years	to	+1.12	aged	8.5	years,	see	growth	chart,	Figure	3).
His	 brother,	 3c,	 was	 born	 at	 42	weeks’	 gestation	 with	 a	 birth	
weight	 of	 4.48	kg	 (SDS	 +2.06).	 Neonatal	 jaundice	 was	 treated	
with	 phototherapy	 at	 postnatal	 days	 1	 and	 14	 but	 persisted	 for	
6	months	 with	 elevated	 transaminases.	 He	 had	 mild	 pulmonary	
branch	stenosis,	speech	delay	and	glue	ear.	At	age	2.3	years,	he	was	
noted	to	have	a	subnormal	FT4	[9.1	pmol/L	(RR	12-	22)]	with	a	nor-





progressed	well	 at	 school;	 his	 speech	 is	now	also	normal.	The	oc-
















right	most	 lane).	 Indeed,	 far	 less	 IGSF1-	 L773P	was	 observed	 at	 the	
plasma	membrane	 than	wild-	type	 IGSF1,	 as	 assessed	by	 cell	 surface	
biotinylation	(Figure	1B,	top	panel).	These	data	indicate	that	the	traffick-
ing	of	IGSF1-	L773P	out	of	the	ER	to	the	plasma	membrane	is	impaired.
3.3 | Additional genetic ascertainment and 
endocrine evaluation
Family	 screening	 identified	 an	 additional	 eight	 hemizygous	 males	





All	 evaluable	 male	 cases	 exhibited	 central	 hypothyroidism	 (FT4	
ranging	from	6.9	to	10.2	pmol/L,	mean	Z-	score	−3.3	±	0.4)	although	
biochemical	 penetrance	was	 variable.	 In	 all	 cases,	 FT3	 concentra-
tions	 were	 maintained	 within	 the	 reference	 range	 (mean	 Z-	score	
−0.8	±	0.8)	despite	a	subnormal	FT4,	and	 in	 three	evaluable	cases,	
this	was	achieved	at	the	expense	of	low/low	normal	reverse	T3	con-
centrations	 (Figures	2	 and	 4).	 Assessment	 of	 physiological	 thyroid	
status	 is	challenging	due	to	a	paucity	of	sensitive	and	specific	bio-
markers;	 however,	we	 screened	 our	 cases	 for	 features	 potentially	
attributable	 to	 tissue	 hypothyroidism	 including	 high	 birth	 weight,	
neonatal	 complications	 of	 hypothyroxinaemia,	 obesity,	 develop-
mental	delay,	growth	 impairment	and	symptoms	such	as	constipa-
tion	and	fatigue	(Table	1).	Three	of	seven	cases	for	whom	data	was	
available	 (3a,	3c,	3g)	 exhibited	birth	weight	SDS	 scores	of	 greater	
than	+2.0	and	case	1a	was	 reportedly	a	 “large	baby”	with	an	esti-
mated	birth	weight	of	around	4.5	kg;	cases	3d	and	3e	exhibited	low	
birth	 weight	 SDS	 which	 may	 have	 been	 attributable	 to	 maternal	
renal	disease.	One	child	and	two	adolescents	(cases	3a,	3h,	and	3i)	
with	 mild-	moderate	 central	 hypothyroidism,	 exhibited	 growth	 re-
tardation	or	a	decline	in	growth	velocity;	as	previously	detailed,	3a	
TABLE  2 Baseline	endocrinology	(Heterozygotes)
Case ID Age (y) TSH (0.3- 5.5 mU/L) fT4 (12- 22 pmol/L) fT3 (3.5- 6.5 pmol/L) PRL (Z score) IGF- 1 (Z score)
1d 66 2.17 13.2a 4.5 −0.9 2.2
2a 44.8 1.81 13.4 NA −1.7 2.9
2b 43.8 2.03 12.4 NA −2.7 NA
2c 42.6 1.08 11.7 4.4 −1.3 0.4
2d 39.9 2.54 14.1 NA 0.8 −1.5
2e 37.3 1.9 12.9 NA −2.3 1.1
2f 45.7 2.87 13.9a 4.1 −1.4 −0.4
2g 44.6 1.75 12.8a 4.6 −0.7 −0.1
2h 33.9 1.47 16.6 4.5b 0.7 1.0
3b 6.2 3.44 15.4 6.3b −2.8 NA
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F IGURE  3 Growth	chart	demonstrating	sequential	height	and	weight	SDS	in	case	3a	(pale	blue).	The	arrow	denotes	commencement	of	
levothyroxine	treatment	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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exhibited	a	growth	response	to	levothyroxine	(Figure	3)	and	3i	also	





neonatal	 hypothermia	 and	 case	 3a	 had	 required	 dietary	 interven-
tion	for	obesity	(Figures	2	and	4;	Table	1).	However,	three	children	
(cases	3d,	3e,	and	3g)	were	apparently	clinically	euthyroid;	despite	
moderately	 subnormal	 FT4	 concentrations.	 Three	 adults	were	 ge-
netically	 ascertained	 in	 their	 6th-	8th	 decades.	 Two	 cases	 (1b,	 1c)	
with	moderate	hypothyroidism	had	previously	been	commenced	on	
levothyroxine	 aged	 56	 and	 59	years	 after	 presenting	with	 fatigue	
and	obesity,	despite	attaining	normal	height.	Case	1a	had	significant	
biochemical	 hypothyroidism	at	 diagnosis	 aged	75.5	years;	 [fT4	6.9	
(RR	12-	22	pmol/L)]	and	we	selected	 this	patient	 for	more	detailed	




CK	204	 (40-	320	mU/L),	 SHBG	36.3	 (10-	57	mmol/L),	 and	his	 IGF-	1	
concentration	(a	positively-	regulated	thyroid	hormone	target	gene)	
was	 also	 inappropriately	 in	 the	 upper	 part	 of	 the	 normal	 range	
given	his	subnormal	fT4	[IGF-	1	25.7	mmol/L,	 (RR	8.5-	30.7,	Z	score	
+1.1)].	 Cognitive	 function	 was	 not	 formally	 characterized	 but	 he	
had	 no	 overt	 neurodevelopmental	 abnormalities	 (Figures	2	 and	 4;	
Table	1,	Supporting	Information	Table	S1)	Basal	metabolic	rate	was	
normal	 (7.8	MJ/d),	 equating	 to	 101.8%	 value	 computed	 using	 the	
Schofield	predictive	equation,20	sleeping	heart	rate	was	unremark-
able	 (55	beats/min,	 RR	46-	67,	mean	55	beats/min)	 and	 clinical	 ex-
amination	 (warm	palms,	 normal	Achilles	 tendon	 reflex,	 lack	of	 dry	
skin	or	hypothyroid	facies)	did	not	reveal	any	other	features	of	hy-
pothyroidism.	Therefore,	although	other	 family	members	with	 less	




Only	 one	 heterozygous	 female	 (case	 2c,	 aged	 42.6	years)	
	exhibited	central	hypothyroidism	[TSH	1.08	mU/L	(RR	0.3-	4.2);	FT4	





ence	 range	 (hemizygotes;	mean	Z-	score	−1.5	±	1.4,	 heterozygotes;	
mean	Z	score	−1.2	±	1.2).	One	hemizygous	adult	and	three	children	
exhibited	 hypoprolactinaemia,	with	 prolactin	 concentrations	 rang-
ing	from	undetectable	(case	3a)	to	subnormal	(cases	3c,	3e,	and	1c)	






The	FSH:LH	ratio	was	 in	 the	upper	part	of	 the	 reference	range	 in	
the	three	male	hemizygous	adults,	mean	2.91	(RR	0.4-	3.4)	(Table	1;	
Table	S1).	Ultrasonography	 in	 case	1a	 confirmed	macro-	orchidism	
(mean	 testicular	 volume	 22.3	mL,	 Z	 score	 +2.4)	 compared	 with	
age-	matched	 reference	 data.19	 Two	 children	 (3h,	 3i)	 had	 clinically	










Two	male	 cases	 had	 either	 low	 normal	 (3i)	 or	 mildly	 subnormal	
(3h)	IGF-	1	concentrations	at	diagnosis;	however,	both	were	evalu-
ated	whilst	hypothyroid	and	peripubertal	(aged	12	and	13	years);	
therefore,	 GH	 deficiency	 could	 not	 be	 definitively	 excluded	 or	
confirmed.	 Case	 3i	 showed	 improved	 growth	 on	 levothyroxine,	
but	 Case	 3h	 was	 still	 growing	 slowly	 at	 age	 14.5	years	 (height	
velocity	 4.1	cm/y,	 height	 142	cm,	 <0.4th	 centile,	 testosterone	
<0.2	nmol/L,	 pubertal	 staging	 G3,	 P1,	 A1,	 testicular	 volumes	
8	mL),	 despite	 low	 normal	 IGF-	1	 (19.7	nmol/L).	 An	 insulin	 toler-
ance	test	(ITT)	after	testosterone	priming	confirmed	growth	hor-
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when	thyroxine	replete,	GH	concentrations	were	insufficient	(GH	





locity,	 this	 resolved	without	 intervention.	Cortisol	 response	was	
preserved	(peak	529	mmol/L).
Paradoxically,	 IGF-	1	 concentrations	 were	 elevated	 in	 two	 of	










A	TRH	 test	was	 performed	 in	 seven	males	 [1	 adult	 (Case	 1a)	 and	
six	 children	 (Cases	 3a,c,d,e,h,i)];	 five	 cases	 underwent	 prolonged	
testing.	The	TSH	peak	occurred	at	20	minutes	 in	all	cases	and	was	
normal	or	exuberant	 (mean	peak	14.4	±	8.6	mU/L	 (RR	12.9	±	3.1));	
however,	 the	maximal	 increment	 in	FT3	and	FT4	 (an	 indirect	 indi-
cator	of	TSH	bioactivity)	was	not	significantly	different	to	controls,	










Irish	kindred.	This	 is	 the	 largest	reported	family	to	date,	with	endo-
crine	 evaluation	 of	 10	 hemizygous	 males	 and	 11	 heterozygous	 fe-
males.	Previously	described	IGSF1	mutations	include	four	whole-	gene	










to	ESPE	criteria.29	Ascertainment	following	 identification	of	an	 IGSF1 
mutation	may	precipitate	diagnosis	of	moderate	central	hypothyroidism	


































cases	were	 obese,	 perhaps	 also	 reflecting	 tissue	 hypothyroidism9 al-










preclude	 development	 of	 symptomatic	 hypothyroidism,	 increased	
conversion	 of	 FT4	 to	 FT3	may	modulate	 tissue	 hypothyroidism	 in	
some	 subjects.4	 Alternatively,	 a	 history	 of	 apparently	 normal	 de-
velopment	 in	 hypothyroid	 adults	 may	 reflect	 evolution	 of	 milder	




IGSF1	 is	 thought	 to	 have	 a	 role	 in	 murine	 TRH	 signalling	 since	
Igsf1	null	mice	exhibit	preserved	hypothalamic	Trh	expression	with	de-
creased	pituitary	Trhr1	mRNA	levels	and	subnormal	TSH	response	to	
exogenous	TRH.4,12	Human	studies	generally	 support	a	 similar	 func-

































acromegaloid	 facies	with	 inappropriately	 preserved	 IGF-	1	 given	 his	
hypothyroidism.	Cortisol	production	was	not	evaluated	systematically	
in	our	kindred;	however,	transient	neonatal	hypocortisolism	has	also	
been	reported	in	IGSF1	deficiency.9	 In	this	context,	 it	 is	noteworthy	











associated	 pubertal	 delay	 and	 GH	 deficiency	 may	 be	 amenable	
to	 treatment	 following	 endocrine	 diagnosis.	 These	 observations	
mandate	 multigenerational	 genetic	 and	 biochemical	 ascertain-
ment	 in	 all	 members	 of	 IGSF1	 deficient	 kindreds	 born	 in	 coun-
tries	such	as	Ireland	and	the	UK,	where	CH	screening	programmes	
fail	 to	detect	CeCH	neonatally,	as	well	as	 in	adults	born	prior	to	
the	 implementation	 of	 the	 screening	 in	 countries	 operating	 T4-	
based	methods.	This	may	be	a	significant	undertaking,	 spanning	
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